{"id":"NCT01281007","sponsor":"EMS","briefTitle":"Efficacy of Oral Famciclovir 125mg Comparing to Aciclovir 200 mg Treatment in Patients With Active Recurrent Genital Herpes","officialTitle":"A Prospective, Randomized, Multicenter Study of the Efficacy and Safety of Famciclovir 125 mg Comparing to Aciclovir 200 mg in Patients With Active Recurrent Genital Herpes","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-07","primaryCompletion":"2015-01","completion":"2015-03","firstPosted":"2011-01-21","resultsPosted":"2015-07-07","lastUpdate":"2021-04-21"},"enrollment":150,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["GENITAL HERPES"],"interventions":[{"type":"DRUG","name":"Famciclovir","otherNames":[]},{"type":"DRUG","name":"Aciclovir","otherNames":[]}],"arms":[{"label":"Famciclovir 125 mg","type":"EXPERIMENTAL"},{"label":"Aciclovir 200 mg","type":"ACTIVE_COMPARATOR"}],"summary":"Recurrent genital herpes is a commonly occurring sexually transmitted disease caused by herpes simplex virus (HSV). There are effective oral prescription antiviral medicines available to reduce the discomfort of symptoms, such as famciclovir and aciclovir.\n\nThis is a phase III, multicenter, randomized, parallel-group study to compare the efficacy and safety of treatment with famciclovir (125 mg) versus aciclovir (200 mg) in patients with active recurrent genital herpes.","primaryOutcome":{"measure":"Efficacy Will be Evaluated by the Proportion of Subjects With Non Herpes Manifestation","timeFrame":"Day 5","effectByArm":[{"arm":"Famciclovir 125 mg","deltaMin":73,"sd":null},{"arm":"Aciclovir 200 mg","deltaMin":52,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":9,"countries":["Brazil"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":75},"commonTop":["Headache"]}}